429 related articles for article (PubMed ID: 14555767)
21. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF).
Hendrix MJ; Seftor EA; Seftor RE; Kirschmann DA; Gardner LM; Boldt HC; Meyer M; Pe'er J; Folberg R
Am J Pathol; 1998 Apr; 152(4):855-63. PubMed ID: 9546344
[TBL] [Abstract][Full Text] [Related]
22. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase.
Fan S; Ma YX; Wang JA; Yuan RQ; Meng Q; Cao Y; Laterra JJ; Goldberg ID; Rosen EM
Oncogene; 2000 Apr; 19(18):2212-23. PubMed ID: 10822371
[TBL] [Abstract][Full Text] [Related]
23. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
24. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
[TBL] [Abstract][Full Text] [Related]
25. Hepatocyte growth factor/scatter factor induces VEGF in human external auditory canal cholesteatoma cell culture.
Naim R; Sadick H; Bayerl C; Riedel F; Schafer C; Bran G; Hormann K
Int J Mol Med; 2005 Jan; 15(1):67-71. PubMed ID: 15583829
[TBL] [Abstract][Full Text] [Related]
26. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
27. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase.
Uruno A; Sugawara A; Kudo M; Satoh F; Saito A; Ito S
Hypertens Res; 2008 Nov; 31(11):2085-96. PubMed ID: 19098381
[TBL] [Abstract][Full Text] [Related]
28. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.
Halaban R; Rubin JS; Funasaka Y; Cobb M; Boulton T; Faletto D; Rosen E; Chan A; Yoko K; White W
Oncogene; 1992 Nov; 7(11):2195-206. PubMed ID: 1331934
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.
Scarpino S; Di Napoli A; Taraboletti G; Cancrini A; Ruco LP
J Pathol; 2005 Jan; 205(1):50-6. PubMed ID: 15526350
[TBL] [Abstract][Full Text] [Related]
30. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
31. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.
Hu B; Guo P; Bar-Joseph I; Imanishi Y; Jarzynka MJ; Bogler O; Mikkelsen T; Hirose T; Nishikawa R; Cheng SY
Oncogene; 2007 Aug; 26(38):5577-86. PubMed ID: 17369861
[TBL] [Abstract][Full Text] [Related]
32. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
[TBL] [Abstract][Full Text] [Related]
33. Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription.
Reisinger K; Kaufmann R; Gille J
J Cell Sci; 2003 Jan; 116(Pt 2):225-38. PubMed ID: 12482909
[TBL] [Abstract][Full Text] [Related]
34. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor.
Kaga T; Kawano H; Sakaguchi M; Nakazawa T; Taniyama Y; Morishita R
Vascul Pharmacol; 2012 Aug; 57(1):3-9. PubMed ID: 22361334
[TBL] [Abstract][Full Text] [Related]
35. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.
Hyder SM; Liang Y; Wu J; Welbern V
Endocr Relat Cancer; 2009 Sep; 16(3):809-17. PubMed ID: 19570906
[TBL] [Abstract][Full Text] [Related]
36. Influence of hepatocyte growth factor/scatter factor (HGF/SF) on fibroblast growth factor-2 (FGF-2) levels in external auditory canal cholesteatoma (EACC) cell culture.
Naim R; Chang RC; Sadick H; Hormann K
In Vivo; 2005; 19(3):599-603. PubMed ID: 15875782
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
38. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
Cao B; Su Y; Oskarsson M; Zhao P; Kort EJ; Fisher RJ; Wang LM; Vande Woude GF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7443-8. PubMed ID: 11416216
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.
Kaio E; Tanaka S; Oka S; Hiyama T; Kitadai Y; Haruma K; Chayama K
Int J Oncol; 2003 Oct; 23(4):901-11. PubMed ID: 12963968
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway.
Paumelle R; Tulasne D; Kherrouche Z; Plaza S; Leroy C; Reveneau S; Vandenbunder B; Fafeur V
Oncogene; 2002 Apr; 21(15):2309-19. PubMed ID: 11948414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
